Browse
Submit Data
Databases
API
Help

Dataset Information

6 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Exploratory observational study of famitinib malate combined with carrillizumab in third-line and post-third-line treatment of colorectal cancer

ABSTRACT: Interventions: Single arm:camrelizumab combined with famitinib Primary outcome(s): Overall Survival Study Design: Single arm

DISEASE(S): Colorectal Cancer

PROVIDER: 2693365 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

Adbelimumab plus famitinib malate and chemotherapy as second-line treatment for metastatic colorectal cancer

Project description:Interventions: experimental group:Adbelimumab+famitinib malate+chemotherapy Primary outcome(s): objective response rate Study Design: Single arm

| 117047 | ecrin-mdr-crc

An exploratory study on optimizing the administration time of furquintinib combined with camrelizumab in the third-line treatment of MSS late colorectal cancer

Project description:Interventions: Test group:Camrelizumab + Fruquintinib Primary outcome(s): progression-free survival Study Design: Single arm

| 2716835 | ecrin-mdr-crc

A single-arm, prospective, open-label clinical study of camrelizumab combined with apatinib mesylate as a third-line treatment for advanced colorectal cancer

Project description:Interventions: single arm:camrelizumab combined with apatinib mesylate Primary outcome(s): PFS Study Design: Single arm

| 2690370 | ecrin-mdr-crc

Single-arm phase II exploratory study of cetuximab combined with camrelizumab in RAS wild-type recurrent or distantly metastatic advanced colorectal cancer after failure of second-line standard therapy

Project description:Interventions: Experimental group:Cetuximab:500mg/m2,d1,q2w Camrelizumab:200mg, d1, q2w Primary outcome(s): Objective response rate Study Design: Single arm

| 85219 | ecrin-mdr-crc

Safety and Efficacy Study of Famitinib in Patients With Advanced Colorectal Adenocarcinoma（FACT）

Project description:Famitinib is a tyrosin-inhibitor agent targeting at c-Kit, VEGFR2, PDGFR, VEGFR3, Flt1 and Flt3, whose anti-tumor and anti-angiogenesis effects have been validated in preclinical tests. In PhaseⅡb study, a significantly improved Progression Free Survival (PFS) was found in patients with advanced colorectal cancer treated with Famitinib compared to placebo. On the other hand, the toxicity of Famitinib was manageable in both PhaseⅠand Ⅱb studies. The purpose of this study is to determine whether Famitinib can improve Overall Survival (OS) compared with placebo in total 540 patients with advanced colorectal cancer who have failed in previously received at least two lines of standard chemotherapy.

| 2185942 | ecrin-mdr-crc

An exploratory clinical study of camrelizumab combined with radiotherapy in the treatment of postoperative or late recurrence of colorectal cancer

Project description:Interventions: Test group :Camrelizumab + radiotherapy Primary outcome(s): Progression-free survival Study Design: Single arm

| 2760326 | ecrin-mdr-crc

Camrelizumab combined with Apatinib in the treatment of patients with advanced gastric cancer and colorectal cancer: single arm exploratory study

Project description:Interventions: Case series:Camrelizumab + Apatinib Primary outcome(s): Objective response rate Study Design: Single arm

| 2686078 | ecrin-mdr-crc

A Study of Famitinib in Patients With Advanced Colorectal Cancer

Project description:Famitinib is a tyrosin-inhibitor agent targeting at c-Kit, VEGFR2, PDGFR, VEGFR3, Flt1 and Flt3, and it’s anti-angiogenesis effect has been viewed in preclinical tests. Phase I study has shown that the toxicity is manageable. The purpose of this study is to determine whether Famitinib can improve progression free survival compared with placebo in patients with advanced colorectal cancer who failed in previous at least two lines of chemotherapy.

| 2137827 | ecrin-mdr-crc

A Study of Famitinib in Patients With Advanced or Metastatic Gastroenteropancreatic Neuroendocrine Tumor

Project description:Famitinib is a tyrosin-inhibitor agent targeting at c-Kit, VEGFR2, PDGFR, VEGFR3, Flt1 and Flt3. Phase I study has shown that the toxicity is manageable. The purpose of this study is to evaluate the efficacy and safety profile of Famitinib in patients with advanced or metastatic Gastroenteropancreatic Neuroendocrine Tumor.

| 2155563 | ecrin-mdr-crc

Eribulin mesylate use as third-line therapy in patients with metastatic breast cancer (VESPRY): a prospective, multicentre, observational study.

Project description:BackgroundIn real-world practice, eribulin mesylate provides significant survival benefit, with a manageable safety profile in heavily pretreated patients with metastatic breast cancer (MBC).MethodsIn this prospective, open-label, multicentre, observational study we evaluated the effectiveness and tolerability of eribulin as third-line treatment in a homogeneous population. The primary endpoints were the safety profile and response in metastatic sites; secondary endpoints included the response in different subtypes, overall response rate (ORR), progression-free survival (PFS) and overall survival (OS).ResultsFrom 2013 to 2016, 118 women were treated in 21 Sicilian institutions; the median age was 58 years (range 29-79), with 69% of patients under 65. The median cycles of eribulin were 5.5 (range 1-26). The most common adverse event was neutropenia (9.3%, 3 cases of grade 3, 4 of grade 4); only 1 case of QT prolongation was reported. Eribulin was effective in controlling metastatic disease in all sites, and it achieved the highest ORR in brain (16%) and liver (14.9%). Median OS was 31.8 months (95% CI 27.9-34.4) and median PFS 5.5 months (95% CI 4.2-6.6). PFS was 5.2 months (95% CI 2.8-8.4) in patients with triple-negative subtype. Median PFS was longer in patients over 65 years (6.1 months, 95% CI 4.4-8.3). In patients who had visceral metastases PFS was 5.5 months (95% CI 95% 3.5-6.6) and OS 33.9 months (95% CI 29.8-40.8).ConclusionsEribulin as third-line treatment shows an acceptable safety profile and a substantial antitumour activity in the treatment of MBC, even in elderly patients and in those with visceral disease.

| S-EPMC6923689 | biostudies-literature

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data